Medtronic PLC $MDT Shares Sold by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH decreased its holdings in shares of Medtronic PLC (NYSE:MDT) by 3.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,533,452 shares of the medical technology company’s stock after selling 93,725 shares during the quarter. Medtronic comprises about 1.1% of Fort Washington Investment Advisors Inc. OH’s investment portfolio, making the stock its 19th biggest position. Fort Washington Investment Advisors Inc. OH owned about 0.20% of Medtronic worth $218,612,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in MDT. Arlington Trust Co LLC increased its stake in Medtronic by 11.6% in the second quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock valued at $91,000 after purchasing an additional 120 shares during the last quarter. Bigelow Investment Advisors LLC lifted its position in Medtronic by 1.1% during the first quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock worth $964,000 after buying an additional 121 shares during the period. Bank & Trust Co boosted its stake in Medtronic by 2.8% in the 2nd quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock worth $342,000 after buying an additional 121 shares during the last quarter. Grove Bank & Trust boosted its stake in Medtronic by 1.2% in the 3rd quarter. Grove Bank & Trust now owns 10,564 shares of the medical technology company’s stock worth $912,000 after buying an additional 124 shares during the last quarter. Finally, Integrity Alliance LLC. boosted its stake in Medtronic by 1.7% in the 2nd quarter. Integrity Alliance LLC. now owns 7,388 shares of the medical technology company’s stock worth $578,000 after buying an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

MDT has been the subject of several recent analyst reports. BTIG Research lowered their price target on Medtronic from $100.00 to $99.00 and set a “buy” rating for the company in a report on Monday. Bank of America increased their price objective on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Weiss Ratings raised shares of Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, September 4th. Stifel Nicolaus raised their target price on shares of Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research report on Wednesday, September 2nd. Finally, Needham & Company LLC restated a “buy” rating on shares of Medtronic in a report on Thursday, September 17th. Seventeen equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and an average target price of $102.88.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Piper Sandler sees a positive read-through for Medtronic. The analyst commentary suggests recent developments may support the investment case for MDT and likely contributed to buying interest. Piper Sandler on Medtronic: Positive Read-Through for MDT
• Positive Sentiment: Medtronic reported final results for its MiniMed Group exchange offer. The transaction gives shareholders additional clarity on the separation and ownership structure of the diabetes business. The reported 18.3% proration indicates demand exceeded the shares available for exchange, a potentially favorable sign for investor interest in MiniMed and Medtronic’s strategic repositioning. Medtronic Announces Final Results of MiniMed Group Exchange Offer
• Neutral Sentiment: Medtronic’s dividend remains attractive to income investors. A comparison with Abbott highlighted MDT’s higher current payout, while Abbott has delivered faster dividend growth. This supports Medtronic’s appeal for yield-focused investors but is more of a long-term valuation consideration than a new earnings catalyst. Medtronic Pays More Today: Abbott Raises Its Dividend Faster
• Neutral Sentiment: Industry reports project strong growth in mHealth and bioelectronic medicine. Medtronic is listed among major participants in both markets, offering potential long-term opportunities, but the reports do not provide company-specific revenue or earnings changes. mHealth Solutions Market Forecasts Growth
• Negative Sentiment: Short interest in MDT increased significantly. Rising bearish positioning could create volatility and signals that some investors remain skeptical, despite the recent share-price strength. Medtronic Sees Significant Increase in Short Interest

Insider Activity

In other news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.27% of the company’s stock.

Medtronic Stock Up 1.2%

Shares of Medtronic stock opened at $94.14 on Thursday. The company has a fifty day moving average price of $90.68 and a 200 day moving average price of $84.88. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The stock has a market cap of $120.41 billion, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of 2.12 and a beta of 0.55.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same period last year, the company posted $1.26 earnings per share. The firm’s revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts forecast that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio is presently 70.94%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.